Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...